Next Article in Journal
Gender-Dependent Effects of Enriched Environment and Social Isolation in Ischemic Retinal Lesion in Adult Rats
Next Article in Special Issue
Involvement of miR-20a in Promoting Gastric Cancer Progression by Targeting Early Growth Response 2 (EGR2)
Previous Article in Journal
Acetylcholinesterase Reactivators (HI-6, Obidoxime, Trimedoxime, K027, K075, K127, K203, K282): Structural Evaluation of Human Serum Albumin Binding and Absorption Kinetics
Previous Article in Special Issue
Non-Coding RNAs: Multi-Tasking Molecules in the Cell
Open AccessArticle

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients

Steinbeis Transfer Center for Proteome Analysis, Schillingallee 68, 18057 Rostock, Germany
Department of Neurology, Division of Neuroimmunology, University of Rostock, Gehlsheimer Str. 20, 18147 Rostock, Germany
Institute of Immunology, University of Rostock, Schillingallee 70, 18055 Rostock, Germany
Institute for Biostatistics and Informatics in Medicine and Ageing Research, University of Rostock, Ernst-Heydemann-Str. 8, 18057 Rostock, Germany
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2013, 14(8), 16087-16110;
Received: 8 June 2013 / Revised: 12 July 2013 / Accepted: 26 July 2013 / Published: 5 August 2013
(This article belongs to the Special Issue Regulation by non-coding RNAs 2013)
MicroRNAs (miRNAs) are small non-coding RNA molecules acting as post-transcriptional regulators of gene expression. They are involved in many biological processes, and their dysregulation is implicated in various diseases, including multiple sclerosis (MS). Interferon-beta (IFN-beta) is widely used as a first-line immunomodulatory treatment of MS patients. Here, we present the first longitudinal study on the miRNA expression changes in response to IFN-beta therapy. Peripheral blood mononuclear cells (PBMC) were obtained before treatment initiation as well as after two days, four days, and one month, from patients with clinically isolated syndrome (CIS) and patients with relapsing-remitting MS (RRMS). We measured the expression of 651 mature miRNAs and about 19,000 mRNAs in parallel using real-time PCR arrays and Affymetrix microarrays. We observed that the up-regulation of IFN-beta-responsive genes is accompanied by a down-regulation of several miRNAs, including members of the mir-29 family. These differentially expressed miRNAs were found to be associated with apoptotic processes and IFN feedback loops. A network of miRNA-mRNA target interactions was constructed by integrating the information from different databases. Our results suggest that miRNA-mediated regulation plays an important role in the mechanisms of action of IFN-beta, not only in the treatment of MS but also in normal immune responses. miRNA expression levels in the blood may serve as a biomarker of the biological effects of IFN-beta therapy that may predict individual disease activity and progression. View Full-Text
Keywords: interferon-beta; multiple sclerosis; peripheral blood; microRNA; gene expression interferon-beta; multiple sclerosis; peripheral blood; microRNA; gene expression
Show Figures

MDPI and ACS Style

Hecker, M.; Thamilarasan, M.; Koczan, D.; Schröder, I.; Flechtner, K.; Freiesleben, S.; Füllen, G.; Thiesen, H.-J.; Zettl, U.K. MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients. Int. J. Mol. Sci. 2013, 14, 16087-16110.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop